Loading...

Purified anti-human CD45RA Antibody

Pricing & Availability
Clone
HI100 (See other available formats)
Regulatory Status
RUO
Workshop
IV N906
Other Names
GP180, L-CA, LCA, LY5, T200, PTPRC
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
A_HI100_Purified_062707
Human peripheral blood platelets stained with purified HI100, followed by anti-mouse IgGs FITC
  • A_HI100_Purified_062707
    Human peripheral blood platelets stained with purified HI100, followed by anti-mouse IgGs FITC
  • B_HI100_PURE_CD45RA_Antibody_SB_111423
    SeqIF™ (sequential immunofluorescence) staining on COMET™ of Purified anti-CD45RA (clone HI100, yellow) on formalin-fixed paraffin-embedded human pancreatic carcinoma tissue at 0.5 µg/mL. Alexa Fluor™ Plus 647 Goat anti-Mouse IgG antibody (Lunaphore, Cat. No. DR647MS) was used as a secondary antibody. Nuclei were counterstained with DAPI (blue). Tissue underwent an all-in-one dewaxing and antigen retrieval preprocessing.
See high resolution SB data...
Cat # Size Price Quantity Check Availability Save
304102 100 µg 36€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45RA is a 205-220 kD single chain type I glycoprotein. It is an exon 4 splice variant of the tyrosine phosphatase CD45. The CD45RA isoform is expressed on resting/naïve T cells, medullary thymocytes, B cells and monocytes. CD45RA enhances both T cell receptor and B cell receptor signaling. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4. CD45 has also been reported to bind galectin-1. CD45 isoform expression can change in response to cytokines.

Product Details
Technical data sheet

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF® - Verified
ICC, IHC-F, IHC-P, PG - Reported in the literature, not verified in house
SB - Community verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤2.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for relevant formats of this clone) include: inhibition of CD45 functions2, immunohistochemical staining of frozen tissue sections3 and formalin-fixed paraffin-embedded tissue sections4, and immunocytochemistry15,16.

Additional Product Notes

For the use of this antibody in spatial biology applications, we have partnered with Lunaphore Technologies for demonstration of our antibodies on the COMET™. The COMET™ platform is an automated, end-to-end spatial biology solution developed for rapid and flexible multiplex tissue profiling. More information on the COMET™ and a complete list of our antibodies that have been demonstrated on the COMET™ can be found here.

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Yamada T, et al. 2002. J. Biol. Chem. 277:28830. (WB, Block)
  3. Weninger W, et al. 2003 J. Immunol. 170:4638. (IHC-F)
  4. Imanguli MM, et al. 2009. Blood. 113:3620 (IHC-P)
  5. Roque S, et al. 2007. J. Immunol. 178:8028. (FC) PubMed
  6. Smeltz RB. 2007. J. Immunol. 178:4786. (FC) PubMed
  7. Palendira U, et al. 2008. Blood (FC) PubMed
  8. Kuttruff S, et al. 2009. Blood 113:358. (FC) PubMed
  9. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  10. Alanio C, et al. 2010. Blood 115:3718. (FC) PubMed
  11. Iannello A, et al. 2010. J. Immunol. 184:114. (FC) PubMed
  12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  13. Guereau-de-Arellan M, et al. 2011. Brain. 134:3578. PubMed
  14. Canque B, et al. 2000. Blood 96:3748. (ICC)
  15. Imanguli MM, et al. 2009. Blood 13:3620. (ICC)
  16. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  17. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Gunawan M, et al. 2017. Sci Rep. . 10.1038/s41598-017-16999-7. PubMed
  2. Evrard M et al. 2018. Immunity. 48(2):364-379 . PubMed
  3. Wagner J et al. 2019. Cell. 177(5):1330-1345 . PubMed
  4. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
  5. Damond N, et al. 2019. Cell Metab. 29:755. PubMed
  6. Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed
  7. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  8. Nicolet BP, et al. 2017. J Immunol. 198:962. PubMed
  9. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  10. Zhao J, et al. 2017. Sci Immunol. 2:eaan5400. PubMed
  11. Hunter S, et al. 2018. J Hepatol. 69:654. PubMed
  12. Yoshihara S, et al. 2019. Front Immunol. 0.545833333. PubMed
  13. Lückel C, et al. 2019. Nat Commun. 4.390277778. PubMed
  14. Martin JC, et al. 2020. Cell. 178(6):1493-1508.e20.. PubMed
  15. Bobardt M, et al. 2020. PLoS One. 15:e0227715. PubMed
  16. Majri SS, et al. 2018. J Immunol. 200:110. PubMed
  17. Oda H, et al. 2019. Front Immunol. 10:479. PubMed
  18. Michlmayr D, et al. 2020. Cell Reports. 31(4):107569. PubMed
  19. Waugh KA, et al. 2020. Cell Reports. 29(7):1893-1908.e4.. PubMed
  20. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
  21. Wu Y, et al. 2007. Infect Immun . 178:2802. PubMed
  22. Guerau-de-Arellano M, et al. 2011. Brain. 134:3578. PubMed
  23. Søgaard O, et al. 2015. PLoS One. 11: 1005142. PubMed
  24. Galbraith MD, et al. 2021. eLife. 10:00. PubMed
  25. Yang R, et al. 2020. Cell. 183(7):1826-1847.e31. PubMed
  26. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  27. Roussel M, et al. 2021. Cell Reports Medicine. 2(6):100291. PubMed
  28. Mishra A, et al. 2021. Cell. 184(13):3394-3409.e20. PubMed
  29. Wastyk HC, et al. 2021. Cell. 184(16):4137-4153.e14. PubMed
  30. Sullivan KD, et al. 2021. Cell Reports. 36(7):109527. PubMed
  31. Taft J, et al. 2021. Cell. 184(17):4447-4463.e20. PubMed
  32. Martin E, et al. 2020. JCI Insight. :5. PubMed
  33. Lazarski CA, et al. 2020. Cytotherapy. . PubMed
  34. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  35. Kennedy-Darling J, et al. 2021. Eur J Immunol. 51:1262. PubMed
  36. Hsiao F, et al. 2020. PLoS Pathog. 16:e1008450. PubMed
  37. Apte SH, et al. 2020. Clin Transl Immunology. 9:e1209. PubMed
  38. NULL, et al. 2022. Cell. 185:916. PubMed
  39. Gañán-Gómez I, et al. 2022. Nat Med. . PubMed
  40. Zhang Y, et al. 2020. Front Immunol. 11:1012. PubMed
  41. Syrimi E, et al. 2021. iScience. 24:103215. PubMed
  42. Taylor JG, et al. 2022. Haematologica. :. PubMed
  43. O'Boyle KC, et al. 2020. Methods Mol Biol. 2111:1. PubMed
  44. Wadley AJ, et al. 2020. Brain Behav Immun Health. 3:100049. PubMed
  45. Sattler A, et al. 2021. Am J Transplant. 21:87. PubMed
  46. Umeda M, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  47. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  48. Cobb DA, et al. 2022. J Immunother Cancer. 10:. PubMed
  49. Baskar R, et al. 2022. Cell Rep Methods. 2:. PubMed
  50. Kondo H, et al. 2022. Front Immunol. 13:836923. PubMed
  51. Alpert A, et al. 2022. Cell Syst. 13:71. PubMed
  52. Leader AM, et al. 2021. Cancer Cell. 39:1594. PubMed
  53. Dao T, et al. 2022. JCI Insight. 7: . PubMed
  54. McCarthy EE, et al. 2022. Cell Rep. 39:110815. PubMed
  55. Feyaerts D, et al. 2022. Cell Rep Med. 3:100680. PubMed
  56. Poon MML, et al. 2023. Nat Immunol. 24:309. PubMed
RRID
AB_314406 (BioLegend Cat. No. 304102)

Antigen Details

Structure
Tyrosine phosphatases, type I transmembrane (exon 4 splicing of CD45 gene), 205-220 kD
Distribution

B cells, naïve T cells, monocytes

Function
Enhances TCR and BCR signaling
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
B cells, Monocytes, T cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Thomas M. 1989. Annu. Rev. Immunol. 7:339.
2. Trowbridge I, et al. 1994. Annu. Rev. Immunol.12:85.

Gene ID
5788 View all products for this Gene ID
UniProt
View information about CD45RA on UniProt.org

Related FAQs

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Go To Top Version: 4    Revision Date: 11.14.2023

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account